Spillage Prevention and Airflow-Pattern Monitoring for High-Shear Process Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Spillage Prevention and Airflow-Pattern Monitoring for High-Shear Process Operations
The author proposes techniques, based on Six Sigma methods, for monitoring such processes to discover their airflow patterns and reduce opportunities for spillage. This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."


Pharmaceutical Technology
Issue 34

Analyze


Figure 5
This phase examines the data gained during the previous experiments. Operators can perform the analysis for the first experiment (i.e., monitoring the process under UV light) through close viewing of the recorded video. If personnel modify the mixing process later, they can evaluate the improvements afterward using the same method. The video sometimes reveals minor details that went unnoticed during the operation. The analysis of the second experiment (i.e., settling plates) can be performed either by observing the plates under a microscope or, if the appropriate material was used, by a technique such as high-performance liquid chromatography, gas chromatography, or ultrahigh-performance liquid chromatography for assay. In the latter case, the plates should be rinsed thoroughly with a solvent, and samples should be prepared carefully. The third experiment (i.e., the particle counter) generates data directly, and operators can analyze the digital recording on the counter.

Improve


Figure 6
When the flaws in the process have been identified, the method for improving the process should be chosen. One method of improving the process is to train the operators to improve their material-handling techniques. Operators can watch the video and review the analysis data generated during the previous phase. Clear visual perception of the material is critical when handling an active ingredient or hazardous chemical that cannot be seen with the naked eye. The operators should have proper safety equipment while they perform critical processes.

An alternative is to improve the equipment design to reduce or eliminate spillage. Most often, a cross-functional team with representatives from the equipment vendor is useful in developing conceptual designs. Once the design is complete, it can be tested with simulation software from companies such as COMSOL (Stockholm) and AspenTech (Cambridge, MA), which will reveal flaws. The airflow monitoring pattern developed during video analysis can be a helpful tool for simulation development (4, 5).

Controls

The final stage after implementation of the changes is to monitor the operation continuously for improvement. Minor improvement is always possible. If possible, process changes should be recorded in the company's continuous-improvement program, which will enable the effectiveness of the changes to be evaluated quarterly or semiannually.

Conclusion

Spillage and dusting is a major challenge in the biopharmaceutical industry when an operation involves micrometer-sized particles. Through continuous improvement and techniques such as Six Sigma, the challenges can be associated with critical process points. This approach enables personnel to pinpoint the problem and provide direction for solutions. The DMAIC model provides an excellent directional approach for solving these problems.

Piyush Viradia is a process engineer at Genzyme, 1125 Pleasant View Tr., Ridgefield, NJ 07663, tel. 201.993.1577,
.

References

1. IBM, "Aligning Lean Six Sigma in Managing Process Development," white paper (IBM, Armonk, NY, August 2002).

2. IKA, Labor Pilot2000/4 mill, MHD module specifications, http://www.ikausa.com/labmixersinline.htm, accessed Apr. 7, 2010.

3. Space Environment Technologies, "ISO 21348 Process for Determining Solar Irradiances Compliance," http://www.spacewx.com/ISO_solar_standard.html, accessed Apr. 7, 2010.

4. P. Jeffries, Chem. Eng. J. 24 (2), 36-41 (2005).

5. A. Agrawal, Chem. Eng. J. 24 (2), 42-49 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here